Clinical Trials Browser

Interventional × ALK Positive Non-small Cell Lung Cancer × lorlatinib × Clear all

NCT07617337 2026-06-01

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

Phase 1 Not yet recruiting

ALK Positive Non-small Cell Lung Cancer

NCT06092086 2023-10-23

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

Phase 2 Recruiting

ALK Positive Non-small Cell Lung Cancer